

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **DISCLOSEABLE AND CONNECTED TRANSACTION: COMPLETION OF ACQUISITION OF 91% INTEREST IN TARGET COMPANY**

Reference is made to the announcement of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 16 April 2025 and the supplemental announcement dated 30 April 2025 (collectively the “**Announcements**”) in relation to the Acquisition of 91% equity interest in the Target Company. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that all the conditions under the Equity Transfer Agreement have been fulfilled, and the Completion took place on 26 June 2025 in accordance with the Equity Transfer Agreement.

Upon Completion, the Company indirectly owns 91% equity interest in the Target Company, and the remaining 9% equity interest in the Target Company is directly owned by Ms. Zhang Yujing, an executive Director. As a result, the Target Company became a non-wholly owned subsidiary of the Company, and its financial results will be consolidated into the financial statements of the Group.

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 26 June 2025

*As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Ms. Zhang Yujing; the non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the independent non-executive directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Tsui Wing Tak.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*